Skip to content

Maximizing the Dietary Pattern of Older Adults: the Effects of Protein Intake on Protein Kinetics

Maximizing the Dietary Pattern of Older Adults: the Effects of Protein Intake on Protein Kinetics

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04830514
Enrollment
44
Registered
2021-04-05
Start date
2021-05-27
Completion date
2022-03-15
Last updated
2023-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Keywords

muscle loss, protein, animal-based protein

Brief summary

A randomized study to demonstrate how animal-based protein-rich food sources can be used by older adults to increase protein intake within pre-existing dietary patterns.

Detailed description

Current dietary patterns of older Americans will be augmented by readily available quality protein sources. Investigators will observe the effects of recommended and common protein intakes on the maintenance of whole-body protein balance and potential for muscle protein anabolism. 3 groups of 10 older subjects will be studied during daily protein intakes. Study duration per subject will be about 2 weeks.

Interventions

OTHERRecommended Dietary Allowance of Protein

0.8 g/kg/day protein intake

OTHERHabitual protein intake

1.0 g/kg/day protein intake

OTHEROptimal Protein Intake

1.5 g/kg/day protein intake

Sponsors

University of Arkansas
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* BMI ≤ 35 kg/m2 * Capable of providing informed consent * COVID-19 negative and/or asymptomatic

Exclusion criteria

* Subject who does not/will not eat animal protein sources. * Body mass index \> 35. * History of chemotherapy or radiation therapy for cancer in the 6 months prior to enrollment. * Use of insulin to control blood sugar level. * Currently receiving androgen (e.g., testosterone) or anabolic (e.g., GH, IGF-I) therapy. * Currently using prescription blood thinning medications. * Unable or unwilling to suspend aspirin use for 7 days prior to Visit 3. * Unwilling to avoid using protein or amino-acid supplements during participation.

Design outcomes

Primary

MeasureTime frameDescription
Whole Body Protein Turnover24 hourIsotope Tracer

Countries

United States

Participant flow

Participants by arm

ArmCount
Recommended Dietary Allowance (RDA) for Protein
(RDA; 0.8g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks. Recommended Dietary Allowance of Protein: 0.8 g/kg/day protein intake
10
Habitual Protein Intake Consistent With Population Level Norms
(NHANES; 1.0g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks. Habitual protein intake: 1.0 g/kg/day protein intake
11
Optimal Protein Intake (OPI)
(OPI; 1.5g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks. Optimal Protein Intake: 1.5 g/kg/day protein intake
9
Total30

Baseline characteristics

CharacteristicRecommended Dietary Allowance (RDA) for ProteinHabitual Protein Intake Consistent With Population Level NormsOptimal Protein Intake (OPI)Total
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
3 Participants3 Participants0 Participants6 Participants
Age, Categorical
Between 18 and 65 years
7 Participants8 Participants9 Participants24 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
10 Participants11 Participants9 Participants30 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants1 Participants1 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
1 Participants1 Participants0 Participants2 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants1 Participants1 Participants
Race (NIH/OMB)
White
9 Participants10 Participants7 Participants26 Participants
Region of Enrollment
United States
10 participants11 participants9 participants30 participants
Sex: Female, Male
Female
5 Participants6 Participants6 Participants17 Participants
Sex: Female, Male
Male
5 Participants5 Participants3 Participants13 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 180 / 140 / 12
other
Total, other adverse events
6 / 183 / 145 / 12
serious
Total, serious adverse events
1 / 180 / 140 / 12

Outcome results

Primary

Whole Body Protein Turnover

Isotope Tracer

Time frame: 24 hour

ArmMeasureValue (MEAN)Dispersion
Recommended Dietary Allowance (RDA) for ProteinWhole Body Protein Turnover-0.16 g/kg lean body mass/dayStandard Deviation 0.08
Habitual Protein Intake Consistent With Population Level NormsWhole Body Protein Turnover-0.17 g/kg lean body mass/dayStandard Deviation 0.11
Optimal Protein Intake (OPI)Whole Body Protein Turnover0.48 g/kg lean body mass/dayStandard Deviation 0.11

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026